Researcher helps develop standards for safe use of histotripsy therapy

August 18, 2014, University of Cincinnati

University of Cincinnati researchers are working with the U.S. Food and Drug Administration to develop a set of regulatory standards to ensure the safe and effective administration of histotripsy therapy used to treat patients with an enlarged prostate.

Histotripsy is a novel form of therapeutic ultrasound that can be applied transcutaneously (across the skin) to liquefy tissue. In addition to treating the prostate, it has applications for treatment of fetal ventricular defects, deep-vein thrombosis, and renal and liver cancer.

Kenneth Bader, PhD, postdoctoral fellow in the division of cardiovascular health and diseases at UC, says the gold standard for treating benign prostatic hyperplasia (BPH, an ) involves physicians using electrocautery or sharp dissection to remove tissue that is restricting urination in patients.

"Although the procedure is highly effective, there is also a significant rate of impotence in patients," says Bader. "Histotripsy is highly targeted and will give physicians a less invasive option."

"Instead of heating the tissue like in most forms of therapeutic ultrasound, histotripsy mechanically deforms it," says Bader. "So what happens is you have the small gas nuclei that are in your body and the ultrasound hits it and causes it to expand very rapidly and it collapses in a process termed cavitation. The mechanical action of that expansion and collapse of the cavitation is what liquefies the tissue to generate the therapy."

"It's like a scrubbing bubble, the same as a detergent breaking up dirt and grime, but in this case we are breaking up tissue," says Bader.

Currently, there are in which surgeons use a histotripsy device to emit ultrasound pulses from outside the patient's body into the prostate. These pulses form a bubble cloud within the prostate that mechanically breaks up the cellular structure of the soft tissue. The surgeon can direct the bubbled cloud to the intended treatment location.

UC researchers are not part of those clinical trials, but are working with the FDA to determine ways to regulate the output of these histotripsy devices as part of a $107,000 grant from the Focused Ultrasound Foundation.

Bader is the principal investigator and Christy Holland, PhD, professor in the division of cardiovascular health and diseases at UC and associate director of research for the UC Heart, Lung and Vascular Institute, along with Kevin Haworth, PhD, assistant professor in the division of cardiovascular health and disease at UC, are co-investigators.

"Will there be any collateral damage using histotripsy?" asks Bader. "Is there a good way to monitor the cavitation and monitor the histotripsy therapy? Part of what we are going to do is look at different settings on the histotripsy device. We are going to consider a range of ultrasound pulse durations. We are going to try to see where there is potential for collateral damage with the shortest and the longest pulse duration typically used on a histotripsy device.

"We look at not only how long is the pulse, but also how loud is the pulse," adds Bader. "We are looking at a soft tone versus a very loud tone. It's the range over which you can generate cavitation that depends on either how loud or how long the ultrasound pulse is."

"We will do numerical simulations to try and predict where the cavitation occurs and where the therapy occurs. These simulations will help with patient treatment planning," says Bader.

At some point what's helping to treat the prostate may help improve the of patients. Histotripsy has been used in animal models to try and break up tissues in the heart for the treatment of congenital heart diseases, and breaking up clots to treat deep-vein thrombosis.

"Right now it is just helping the FDA understand histotripsy for BPH, but that will open up a whole other flood gate of applications."

Explore further: New information on transcranial ultrasound therapy

Related Stories

New information on transcranial ultrasound therapy

August 4, 2014
A recent study completed at the University of Eastern Finland provides new information on the limitations and potential new directions for the future development of transcranial ultrasound therapy.

Study finds plasmin—delivered through a bubble—more effective than tPA in busting clots

May 15, 2013
A new study from the University of Cincinnati has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen ...

FDA OKs implant for enlarged prostate symptoms

September 13, 2013
(AP)—Federal health regulators have approved the first permanent implant to treat men's urinary problems caused by an enlarged prostate.

Nonsurgical treatment for enlarged prostate on the horizon

June 23, 2014
You just cannot ignore your symptoms any longer. You find yourself getting up many times every night with the urgency to urinate. Saw palmetto, even high doses of the highest-quality type, didn't work.

New non-invasive technique controls size of molecules penetrating the blood-brain barrier

August 14, 2014
A new technique developed by Elisa Konofagou, associate professor of biomedical engineering and radiology at Columbia Engineering, has demonstrated for the first time that the size of molecules penetrating the blood-brain ...

Focal blood-brain-barrier disruption with high-frequency pulsed electric fields

August 12, 2014
A team of researchers from the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences have developed a new way of using electricity to open the blood-brain-barrier (BBB). The Vascular Enabled Integrated ...

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.